Cargando…

Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

SMARCA4 and EZH2 are two functional key players of their respective antagonizing chromatin remodeling complexes SWI/SNF and PRC2. EZH2 inhibitory drugs may abrogate pro-oncogenic features of PRC2 and turn the balance to cell differentiation via SWI/SNF activity in cancers. SMARCA4 and EZH2 expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leitner, Katharina, Tsibulak, Irina, Wieser, Verena, Knoll, Katharina, Reimer, Daniel, Marth, Christian, Fiegl, Heidi, Zeimet, Alain G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684284/ https://www.ncbi.nlm.nih.gov/pubmed/33230143 http://dx.doi.org/10.1038/s41598-020-77532-x

Ejemplares similares

Tumor necrosis factor receptor modulator spermatogenesis‐associated protein 2 is a novel predictor of outcome in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2019)

Clinical Impact of RANK Signalling in Ovarian Cancer
por: Wieser, Verena, et al.
Publicado: (2019)

The miR-34 family and its clinical significance in ovarian cancer
por: Welponer, Hannah, et al.
Publicado: (2020)

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2018)

High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome
por: Wolf, Dominik, et al.
Publicado: (2019)

The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective
por: Knoll, Katharina, et al.
Publicado: (2021)

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers
por: Notaro, Sara, et al.
Publicado: (2016)

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer
por: Azim, Samira Abdel, et al.
Publicado: (2016)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

A comparison of four technologies for detecting p53 aggregates in ovarian cancer
por: Heinzl, Nicole, et al.
Publicado: (2022)

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR
por: Notaro, Sara, et al.
Publicado: (2016)

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer
por: Schmid, Gabriel, et al.
Publicado: (2016)

Evaluation of Vav3.1 as prognostic marker in endometrial cancer
por: Boesch, Maximilian, et al.
Publicado: (2018)

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2022)

Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer
por: Luger, Anna K., et al.
Publicado: (2020)

Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA 125 – a Prospective Cohort Trial
por: Azim, Samira Abdel, et al.
Publicado: (2021)

Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data
por: Steinkasserer, Lena, et al.
Publicado: (2021)

Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens
por: Schirmer, Uwe, et al.
Publicado: (2013)

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens
por: Schirmer, Uwe, et al.
Publicado: (2018)

AGO Austria recommendations for genetic testing of patients with ovarian cancer
por: Marth, Christian, et al.
Publicado: (2015)

Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective
por: Tsibulak, Irina, et al.
Publicado: (2020)

Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas
por: Urer, Halide Nur, et al.
Publicado: (2023)

Endometroid carcinoma developing in endometriosis over the symphysis pubis()
por: Peer, Michaela, et al.
Publicado: (2013)

Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours
por: Genestie, Catherine, et al.
Publicado: (2019)

SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines
por: Ehrenhöfer-Wölfer, Katharina, et al.
Publicado: (2019)

Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report
por: Braun, Stephan, et al.
Publicado: (2011)

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS)
por: Zeimet, Alain G., et al.
Publicado: (2017)

High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer
por: Guerrero-Martínez, Jose A., et al.
Publicado: (2018)

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
por: Cantley, Jennifer, et al.
Publicado: (2022)

High prevalence of side population in human cancer cell lines
por: Boesch, Maximilian, et al.
Publicado: (2016)

Complex Alternative Splicing of the Smarca2 Gene Suggests the Importance of Smarca2-B Variants
por: Yang, Min, et al.
Publicado: (2011)

Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2015)

Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type
por: Jelinic, Petar, et al.
Publicado: (2016)

SMARCA4 germline gene mutation in a patient with epithelial ovarian: A case report
por: Muppala, Reshma, et al.
Publicado: (2017)

Ovarian carcinoma in children with constitutional mutation of SMARCA4: single-family report and literature review
por: Pastorczak, Agata, et al.
Publicado: (2021)

Coordinated epigenetic regulation of Engrailed-1 by the chromatin remodelers Smarca1 and Smarca5 mediates cerebellar morphogenesis
por: Alvarez-Saavedra, Matias, et al.
Publicado: (2013)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.
por: Zeimet, A. G., et al.
Publicado: (1997)

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics
por: Boesch, Maximilian, et al.
Publicado: (2014)

Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer
por: Xu, Xiaoli, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eni1pouf7p4r2tlnti43gsvsgm